September 1, 2021
In a second series of combined behavioral, neuroanatomical, and genomic studies in an animal model of anxiety and depression, the Cognigenics scientific team successfully demonstrated their platform technology delivers a uniquely-designed CRISPR cargo to cellular targets in the brain associated specifically with anxiety, depression, and emotional memory. The genomic modification of the specific cell targets occurs in animal treatments which were previously targeted in Cognigenics’ first experiment, which significantly ameliorated stress and anxiety. A third series of multimodal genetic neuroengineering experiments is underway to determine the time-dose interactive effects of the treatments using longer time courses and varying doses.
June 10, 2021
The company’s first behavioral experiment demonstrated statistically-significant anxiety reduction in mice receiving our gene therapy versus a control group.
April 15, 2021
Reagents manufactured for mice behavioral experiment.
March 24, 2021
Design completed for mice anxiety behavior experiment.
February 11, 2021
The company received additional angel funding.
January 6, 2021
Decision made to test wild-type mice anxiety reduction with intranasal CRISPR delivery.
November 27, 2020
Transgenic mice founder generation born.
October 16, 2020
Transgenic embryonic stem cells grown.
September 5, 2020
CRISPR reagents formulated for transgenic experiment.
August 21, 2020
Design competed for CRISPR-Cas9 reagents for research experiments.
July 15, 2020
The company received initial funding from early angel investors.
June 26, 2019
Cognigenics, LLC incorporated by Dr. Dean Radin, John Mee and Dr. Barry Linder.